- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02799849
Metabolism Characteristics in the Children With Narcolepsy (Narcolepsy)
Is There a Change in the Total Metabolism Over 24 Hours for Narcoleptic Children That Could Explain Their Tendency to Obesity?
A significant weight gain and obesity are observed for most patients with narcolepsy, mainly at the beginning of the disease and narcolepsy in young children. There is no specific study on the population and the consequences of overweight in the lives of these long-term patients. Narcoleptic patients gain weight significantly at the onset of their illness. It is also known that weight gain is not related to the treatment of narcolepsy. The etiology of obesity in narcoleptic patients is not established. Several assumptions were made (physical activity, leptin diet, metabolism). The reason and the pathophysiology of overweight and obesity in this population therefore remain unclear.
In this study, potential change in the total metabolism (24h) for narcoleptic children that could explain their tendency to obesity will be assessed ?
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Patricia Franco, MD
- Phone Number: +33 04 27 85 60 52
- Email: patricia.franco@chu-lyon.fr
Study Contact Backup
- Name: Sonia Galletti
- Phone Number: +33 04 27 85 77 39
- Email: Sonia.galletti@chu-lyon.fr
Study Locations
-
-
-
Bron, France, 69677
- Recruiting
- Service d'Exploration et pathologie du sommeil, Hôpital Femme Mère Enfant
-
Contact:
- Patricia Franco, MD
- Phone Number: +33 04 27 85 60 52
- Email: patricia.franco@chu-lyon.fr
-
Contact:
- Sonia Galletti
- Phone Number: +33 04 27 85 77 39
- Email: Sonia.galletti@chu-lyon.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
NARCOLEPTIC PATIENTS
- Girl or boy age> 6 years <18 years;
- Narcoleptic: defined by the ICSD diagnostic criteria 2 (International Classification of Sleep Disorders)
- Beginning of the troubles there more than 6 months
- Parental consent and agreement of the child.
HYPERSOMNIC PATIENTS
- Girl or boy age> 6 years <18 years;
- Hypersomnic : defined by the ICSD diagnostic criteria 2 (International Classification of Sleep Disorders)
- Beginning of the troubles there more than 6 months
- Parental consent and agreement of the child.
Exclusion Criteria:
NARCOLEPTIC PATIENTS
- Secondary Narcolepsy;
- Narcolepsy already treated with psychostimulant or anticataplectic;
- Restless legs;
- Sleep apnea syndrome;
- Obesity known outside narcolepsy cause;
- Absence of parental consent.
HYPERSOMNIC PATIENTS
- symptomatic or secondary hypersomnia;
- Hypersomnia already treated psychostimulant or anticataplectic; Restless legs;
- Sleep apnea syndrome;
- Pathology neurological, psychiatric, endocrine or concurrent;
- Lack of parental consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Narcoleptic patients
|
|
Other: hypersomnic patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of the metabolism at home
Time Frame: 15 days
|
Total energy expenditure in kilocalories per minute, including basal metabolic rate (MET) metabolism related to the activity (EEA), and physical activity (PA) measured by accelerometer (Actical) evaluated at home (15 days including scholar and non-scholar days).
|
15 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of the metabolism at hospital
Time Frame: 18 days
|
Total energy expenditure in kilocalories per minute, including basal metabolic rate (MET) metabolism related to the activity (EEA), and physical activity (PA) measured by accelerometer (Actical) evaluated at hospital over 24 hours.
|
18 days
|
Basal energy expenditure
Time Frame: 18 days
|
The basal metabolism (MET) measured by accelerometer (Actical, BodyMedia SW Actiheart) will be compared to the values of energy expenditure (kcal) measured by indirect calorimetry fasting.
|
18 days
|
Energy expenditure and diet-induced thermogenesis
Time Frame: 18 days
|
Energy expenditure (kcal) measured by indirect calorimetry after lunch (with counting calories ingested).
|
18 days
|
Sympathetic activity
Time Frame: 18 days
|
Estimated from IBI (Interbeat Interval) measured by Actiheart.
|
18 days
|
Food intake
Time Frame: 18 days
|
Caloric intake evaluation (kcal per day) during hospitalization (food intake recording) and at home during three days ( two days during the week and one day during the week-end) evaluated by questionnary.
|
18 days
|
Fasting peptide YY
Time Frame: 18 days
|
18 days
|
|
Body weight
Time Frame: 18 days
|
bodyweight (kg)
|
18 days
|
Body height
Time Frame: 18 days
|
Body height (cm)
|
18 days
|
Waist and hips circumference
Time Frame: 18 days
|
Waist and hips circumference (cm)
|
18 days
|
Measurement of neck
Time Frame: 18 days
|
Measurement of neck (cm)
|
18 days
|
Anthropometric measurements
Time Frame: 18 days
|
Measurement of BMI Z-score
|
18 days
|
Appetite
Time Frame: 18 days
|
appetite evaluation by visual analog scale before each meal
|
18 days
|
Hunger
Time Frame: 18 days
|
hunger evaluation by visual analog scale before each meal
|
18 days
|
Fasting IL6-8 levels
Time Frame: 18 days
|
18 days
|
|
Fasting adiponectin
Time Frame: 18 days
|
18 days
|
|
Fasting resistin
Time Frame: 18 days
|
18 days
|
|
Fasting MCP1
Time Frame: 18 days
|
18 days
|
|
Fasting PostPrandial
Time Frame: 18 days
|
18 days
|
|
Fasting GLP1 (glucagon-like peptide-1)
Time Frame: 18 days
|
18 days
|
|
Fasting Hba1C
Time Frame: 18 days
|
18 days
|
|
Body mass index z score
Time Frame: 18 days
|
18 days
|
|
sleep duration
Time Frame: 18 days
|
18 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012-759
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Narcolepsy
-
University of Dublin, Trinity CollegeSt. James's Hospital, IrelandSuspendedNarcolepsy | Hypersomnolence | Narcolepsy Type 1 | Narcolepsy Without Cataplexy | Narcolepsy With Cataplexy | Narcolepsy 1 | Narcolepsy and HypersomniaIreland
-
Northwestern UniversityActive, not recruitingNarcolepsy | Narcolepsy Type 1 | Narcolepsy Without Cataplexy | Narcolepsy With Cataplexy | Narcolepsy Type 2United States
-
NLS PharmaceuticsCompletedNarcolepsy | Narcolepsy Without Cataplexy | Narcolepsy With CataplexyUnited States
-
Boston Children's HospitalAmerican Academy of Sleep MedicineRecruitingIdiopathic Hypersomnia | Narcolepsy Type 1 | Narcolepsy Type 2United States
-
NLS PharmaceuticsNot yet recruitingNarcolepsy Type 1 | Narcolepsy With Cataplexy
-
TakedaRecruitingNarcolepsy Type 1 | Narcolepsy Type 2Spain, Germany, United States, Italy, Netherlands, Japan, France, Norway, Australia, Finland, Switzerland, Sweden
-
Northwestern UniversityNational Center for Complementary and Integrative Health (NCCIH)CompletedNarcolepsy | Narcolepsy Without Cataplexy | Narcolepsy With CataplexyUnited States
-
BioprojetActive, not recruitingNarcolepsy Without Cataplexy | Narcolepsy With CataplexyFrance, Italy, Russian Federation, Finland, Netherlands
-
TakedaTerminatedNarcolepsy Type 1 (NT1) | Narcolepsy Type 2 (NT2)China, United States, Korea, Republic of, France, Italy, Finland, Spain, Czechia, Canada, Japan, Hungary, Netherlands
-
Emory UniversityNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingIdiopathic Hypersomnia | Narcolepsy Without Cataplexy | Narcolepsy With CataplexyUnited States
Clinical Trials on Sleep and metabolism assessment
-
University of AberdeenNHS GrampianCompleted
-
Pennington Biomedical Research CenterNational Institute of General Medical Sciences (NIGMS)Completed
-
Afyonkarahisar Health Sciences UniversityRecruitingMusculoskeletal Diseases | Carpal Tunnel Syndrome | Sleep Quality | Ultrasound | Median Nerve DiseaseTurkey
-
Rashid Centre for Diabetes and ResearchCompletedType 2 Diabetes Mellitus
-
Université Catholique de LouvainRecruiting
-
University of Texas at AustinRecruitingSleep DisturbanceUnited States
-
Assistance Publique Hopitaux De MarseilleUnknownRespiratory Disorder in Patient With Gestational DiabetesFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBreast Cancer | Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer... and other conditionsUnited States
-
Satellite HealthcareCompletedEnd Stage Renal Disease | Chronic Kidney DiseaseUnited States
-
University Hospital, RouenNot yet recruitingIrritable Bowel SyndromeFrance